Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Bangbo Zhao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5035660592. Sources: OpenAlex.

Their work

Papers
31 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 3 papers · 2022: 5 papers · 2023: 6 papers · 2024: 6 papers · 2025: 5 papers · 2026: 3 papers

Papers 31

  1. IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. Co-author DOI 10.1016/j.gendis.2025.101866↗
  2. Effect of TGFβ-ITGB6 feedback loop on liver metastasis in SMAD4 wild-type pancreatic cancer. Co-author DOI 10.1097/cm9.0000000000003722↗
  3. Multidimensional 5-hydroxymethylcytosine features in cell-free DNA enable the detection, staging and subtyping of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40364-026-00988-y↗
  4. Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. Co-author DOI 10.1007/s10555-025-10297-9↗
  5. Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. Co-author DOI 10.1016/j.canlet.2025.217864↗
  6. Phthalocyanine and photodynamic therapy relieve albumin paclitaxel and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2025.114455↗
  7. EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling. Co-author DOI 10.1186/s12935-025-04000-9↗
  8. Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA. Co-author DOI 10.7150/jca.110659↗
  9. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… First author DOI 10.1002/jev2.12488↗
  10. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. First author DOI 10.1007/s13402-024-00925-x↗
  11. Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets. Co-author DOI 10.1016/j.bbcan.2024.189183↗
  12. Circulating tumor cells in pancreatic cancer: more than liquid biopsy. Co-author DOI 10.1177/17588359241284935↗
  13. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. Co-author DOI 10.1186/s12935-024-03456-5↗
  14. Construction of a prognostic model with exosome biogenesis- and release-related genes and identification of RAB27B in immune infiltration of pancreatic cancer. Co-author DOI 10.21037/tcr-24-54↗
  15. Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. First author DOI 10.1007/s13402-023-00897-4↗
  16. Prognostic value and immune infiltration of ARMC10 in pancreatic adenocarcinoma via integrated bioinformatics analyses. Co-author DOI 10.1016/j.heliyon.2023.e20464↗
  17. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Co-author DOI 10.1038/s41419-023-05711-5↗
  18. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Co-author DOI 10.1186/s12967-023-04043-4↗
  19. Pancreatic cancer stemness: dynamic status in malignant progression. Co-author DOI 10.1186/s13046-023-02693-2↗
  20. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pgen.1010847↗
  21. Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. Co-author DOI 10.1016/j.heliyon.2022.e10416↗
  22. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Co-author DOI 10.1186/s12935-022-02768-8↗
  23. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Co-author DOI 10.1186/s12935-022-02785-7↗
  24. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs Co-author DOI 10.21203/rs.3.rs-1759071/v2↗
  25. Long Noncoding RNA and Circular RNA: Two Rising Stars in Regulating Epithelial-Mesenchymal Transition of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.910678↗
  26. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs. Co-author DOI 10.1007/s00018-021-03908-5↗
  27. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. First author DOI 10.1007/s13402-021-00651-8↗
  28. The role of autophagy in pancreatic cancer progression. Co-author DOI 10.1016/j.bbcan.2021.188592↗
  29. A novel prognostic marker and immunogenic membrane antigen: prohibitin (PHB) in pancreatic cancer. Co-author DOI 10.1038/s41424-018-0044-1↗
  30. E‑cadherin is downregulated by microenvironmental changes in pancreatic cancer and induces EMT. Co-author DOI 10.3892/or.2018.6528↗
  31. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. First author DOI 10.7150/jca.17622↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zeru Li · 27 shared papers, 2021–2026 · strength 5.86
  2. Weibin Wang · 22 shared papers, 2018–2026 · strength 4.48
  3. Yutong Zhao · 15 shared papers, 2022–2026 · strength 3.43
  4. Yuanyang Wang · 16 shared papers, 2021–2024 · strength 2.87
  5. Cheng Yong Qin · 10 shared papers, 2022–2026 · strength 2.36
  6. Cheng‐Feng Qin · 12 shared papers, 2021–2024 · strength 2.24
  7. Xiaoying Yang · 12 shared papers, 2021–2024 · strength 2.06
  8. Tianyu Li · 8 shared papers, 2024–2026 · strength 1.99
  9. Weibin Wang · 8 shared papers, 2018–2026 · strength 1.73
  10. Tianyu Li · 9 shared papers, 2022–2024 · strength 1.73
  11. Cheng Qin · 6 shared papers, 2022–2026 · strength 1.43
  12. Tianhao Li · 5 shared papers, 2021–2024 · strength 0.84
  13. Tianhao Li · 5 shared papers, 2022–2023 · strength 0.83
  14. Haoyu Shi · 3 shared papers, 2025–2026 · strength 0.78
  15. Yiping Xie · 3 shared papers, 2025–2026 · strength 0.75
  16. Xingtong Zhou · 4 shared papers, 2021–2024 · strength 0.71
  17. Yutong Zhao · 2 shared papers, 2026 · strength 0.67
  18. Yupei Zhao · 4 shared papers, 2017–2024 · strength 0.49
  19. Haoyu Shi · 1 shared paper, 2026 · strength 0.32
  20. Yuanyang Wang · 1 shared paper, 2025 · strength 0.27
  21. Lin Chen · 1 shared paper, 2024 · strength 0.23
  22. Jun Lü · 2 shared papers, 2018 · strength 0.19
  23. Gang Yang · 1 shared paper, 2021 · strength 0.17
  24. Yang Yu · 1 shared paper, 2018 · strength 0.09
  25. Taiping Zhang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.